Julie R. Brahmer, MD, discusses data for atezolizumab plus platinum/etoposide versus platinum/etoposide alone in patients with small cell lung cancer in the IMpower133 trial.
Julie R. Brahmer, MD, co-director of the Upper Aerodigestive Department in the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Medicine, discusses data for atezolizumab (Tecentriq) plus carboplatin/etoposide versus carboplatin/etoposide alone in patients with small cell lung cancer (SCLC) in the IMpower133 trial.
Brahmer says these data showed that the addition of the immunotherapy improved progression-free survival in these patients. However, it did not improve the response rate.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More